Delving into the Latest Updates on Inactivated SARS-CoV-2 vaccine (Vero cell) (Beijing Bio-Institute) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

BBIBP-CORV, 众爱可维

+ [1]

Target

SARS-CoV-2 antigen

Mechanism

SARS-CoV-2 antigen inhibitors

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

Beijing Bio-Institute Biological Products Co. Ltd.

Active Organization

Beijing Bio-Institute Biological Products Co. Ltd.

Inactive Organization

Laboratorio Elea Phoenix SA

Drug Highest PhaseApproved

First Approval Date

AE (09 Dec 2020),

COVID-19

RegulationConditional marketing approval (CN)

Login to view timeline

Various COVID-19 vaccines can affect the immune system. Discrepancies have been noted in immune system characteristics, such as T-lymphocyte levels, between vaccinated and non-vaccinated individuals. This study investigates the variations in immune responses among the four administered COVID-19 vaccines, influencing factors, and clinical outcomes in Jordan. A total of 350 adults, who were at least two doses vaccinated, were interviewed and blood samples were collected for subsequent laboratory analyses. The study involved the quantification of T-cells specifically targeting anti-SARS CoV-2 using Flow cytometry analysis. BNT162b2 (Pfizer) recipients displayed significantly higher CD3⁺/CD4⁺ T-helper cell responses (90.84%, 87.46% - 94.22%) compared to non-Pfizer-BioNTech recipients {BBIBP-CorV (Sinopharm) and Sputnik V (Gamaleya Research Institute), then ChAdOx1 nCoV-19 (AstraZeneca)} (83.62%, 77.91% - 89.33%). The CD3⁺/CD8⁺ (T cytotoxic) level was notably elevated in non-Pfizer-BioNTech recipients {Sinopharm and Sputnik V then ChAdOx1 nCoV-19 AstraZeneca (73.94%, 69.38% - 78.49%) compared to BNT162b2 (Pfizer) recipients (58.26%, 53.07% - 63.44%). The CD3⁺ (T-cells) level showed no significant difference between BNT162b2 recipients (73.74%) and non-Pfizer-BioNTech recipients (77.83%), with both types generating T-cells. Comparing two doses of non-Pfizer-BioNTech vaccines with the third dose of BNT162b2 recipients (Pfizer), no difference in the type of immune reaction was observed, with non-Pfizer-BioNTech recipients still stimulating endogenous pathways like cell-mediated cytotoxic effects for cells. All COVID-19 vaccines administered in Jordan were effective, with respect to the total number of T cells. Non-Pfizer-BioNTech had higher in toxic T-cells and Pfizer-BioNTech was higher in helper T-cells that stimulate plasma cells to produce antibodies.

01 Nov 2024·Immunity, Inflammation and Disease

Immunogenicity of two‐dose sinopharm BBIB‐CorV vaccine in Morocco: One‐year follow‐up and neutralizing activity against severe acute respiratory syndrome coronavirus 2 variants of concern

Article

Author: El Fahime, Elmostafa ; Bouaiti, Elarbi ; Ennibi, Khalid ; kochri, Safae el ; Belayachi, Lamiae ; Gala, Jean Luc ; Bakkouri, Karim el ; Touil, Nadia ; El Annaz, Hicham ; Rhazzar, Zineb ; Ghammaz, Hamza ; Nyabi, Omar ; Elouennass, Mostafa ; Ouarab, Maha ; Hemlali, Mouhssine

AbstractBackgroundThis study aimed to evaluate the immunogenicity of a two‐dose Sinopharm BBIB‐CorV (Vero cells) vaccine against SARS‐CoV‐2, at 28 days, 6 months, and 1‐year postvaccination. And assess the capacity of two‐dose vaccine recipients to neutralize SARS‐CoV‐2 strains B.1 (Wuhan/D614G), B.1.1.7 (Alpha), AY.33 (Delta), or BA.5.2.2 (Omicron) variants of concern (VOCs).MethodsA prospective matched case–control cohort study was conducted at the Military Hospital of Rabat, Morocco between February 2021 and 2022. Immunogenicity was evaluated by standard Microneutralization (MN) assay against four variants (Wuhan D614G, Alpha, Delta, and Omicron).ResultsThe overall positive neutralizing rates for vaccine recipients against B.1 D614G were 72.09%, 74.82%, and 75.19% on 28‐, 180‐, 365‐ day respectively. The proportion of NAbs targeting the Wuhan D614G, and Alpha variants under the BBIBP‐CorV vaccination was high on Day 28‐ and 6 months postvaccination.ConclusionThe immunogenic response to the newly emerging SARS‐CoV‐2 variants of concern (VOCs), such as Delta and Omicron was comparatively reduced. As a result, it is recommended that additional boost vaccinations be considered.

18 Oct 2024·Medicine

Influencing factors of antibody response after 2 doses of inactivated COVID-19 vaccine among adults aged ≥18 years in Chongqing, China: A cross-sectional serological study

Article

Author: Li, Jianqiao ; Xu, Jiawei ; Liu, Yu ; Wang, Qing

The study aimed to explore the influencing factors after 2 doses of inactivated COVID-19 vaccines (Sinopharm/BBIBP-CorV) in the real world. We conducted a cross-sectional serological study involving 316 volunteers aged ≧ 18 years from 7 vaccination hospitals in the Yubei districts, Yuzhong districts, and Jiulongpo districts of Chongqing. Serum samples were obtained about 1 month after 2 dose vaccination, and Nabs were tested using the pseudovirus-based neutralizing assay. Chi-square or Fisher exact tests were used to analyze the seropositive rates, while the Kruskal–Wallis H or Mann–Whitney U tests were used to analyze differences in Nabs level among stratified groups. Logistic regression analyses were conducted to identify the influencing factors. The results showed that seropositive rates was 76.27% and the GMT was 26.13 (95% CI: 23.03–29.66) after 2 doses of COVID-19 inactivated vaccination. The risk of being seropositive in 18 to 29, 30 to 39, 40 to 49, 50 to 59, and 60 to 69 years were 12.808-fold, 8.041-fold, 7.818-fold, 6.275-fold, 1.429-fold compared with the people aged ≥ 70 years (P < .05), and the risk of being seropositive of intervals 15 to 21 and 22 to 28 days were 0.273-fold and 0.286-fold compared with >28 days (P < .05), respectively. In conclusion, age may be a risk factor for reduced antibody production, and longer vaccination intervals-may be a protective factor that increases antibody production. These findings contribute to informing future vaccination strategies.

100 Deals associated with Inactivated SARS-CoV-2 vaccine (Vero cell) (Beijing Bio-Institute)

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
COVID-19	AE	Beijing Bio-Institute Biological Products Co. Ltd.	09 Dec 2020

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Preclinical	AR	Laboratorio Elea Phoenix SA	16 Sep 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05249816 (Pubmed \| Nat Commun) Manual	Phase 3	COVID-19	3,147,869	BBIBP-CorV	wvlzmvkbtd(sfdgoqcsnu) = ymcyvbbfsp lubefvndlz (uvsbppyxeb, 82.2 - 89.0) View more	-	09 Jun 2022
ChiCTR2000034780 \| NCT04510207 (CNBG2020003SQ, Pubmed) Manual	Phase 3	COVID-19	40,382	Inactivated COVID-19 Vaccine WIV04	(ubhqdgpbuz) = niurrlvoow qdywoaiqyr (yffenselpe ) View more	Positive	26 May 2021
	Phase 3	COVID-19	40,382	Inactivated COVID-19 Vaccine HB02	(ubhqdgpbuz) = zvzxkdtzaa qdywoaiqyr (yffenselpe ) View more	Positive	26 May 2021